TCDA

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic

Did you know?

Capital expenditures decreased by 94% from FY20 to FY21.

Current Price

$0.11

Profile

Valuation (TTM)

Market Cap$6.27M

P/E-0.05

EV—

P/B28.75

Shares Out58.03M

P/Sales—

Revenue$0.00

EV/EBITDA—

TCDA (TCDA) Financial Statements

TCDA Financial Data

EBITDA$-123.70M

Revenue (TTM)$0.00

Gross Profit (TTM)$0.00

Gross Margin—

Operating Margin—

ROE-61427.52%

ROA-79.47%

Debt/Equity649.28

Current Ratio4.94

FCF$-140.16M

FCF Yield-2236.38%

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA—

200-Day MA—

Shares Outstanding0.06B

TCDA Computed Insights

FCF$-140.16M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

TCDA Financial Statements & Data

TCDA (TCDA) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of TCDA's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-123.70M. Earnings per share (EPS) is $-3.44. The P/E ratio is -0.05. Market capitalization is $6.27M.

Free cash flow (FCF) is $-140.16M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 6 years from FY16 to FY21. Net income history spans 6 years. Free cash flow and capital expenditure data spans 6 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use TCDA's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.